Table 1. Clinical results of PRRT with either 90Y-octreotide or 177Lu-octreotate in GEP NETs.
| Agent | Schedule | Patients | CR | PR | DCR | Progression at baseline | Response criteria | Outcome (median PFS or TTP) |
|---|---|---|---|---|---|---|---|---|
| 90Y-octreotide | 7.4 GBq/sqm in 4 cycles (26) | 36 GEP | 4% | 20% | 92% | 100% | WHO | NA |
| 2.96–5.55 GBq/cycle ×2 (16) | 21 GEP | 0% | 28% | 71% | NA | WHO | TTP 10 m | |
| 0.93–2.78 GB/sqm/cycle (27) | 58 GEP | 0% | 9% | 71% | 81% | SWOG | TTP 29 m | |
| 4.4 GBq/cycle ×3 (18) | 90 SI | 0% | 4% | 74.4% | 100% | SWOG | PFS 16 m | |
| 1–10 cycles (median 2), various activity (19) | 821 GEP | 0.2% | 38% | NA | NA | RECIST | NA | |
| 177Lu-octreotate | 27.8–29.6 GBq in 3–4 cycles (20) | 310 GEP | 2% | 28% | 81% | 43% | SWOG | PFS 33 months |
| 3.7–29.2 GBq in 4–6 cycles of 3.7–7.4 GBq (21) | 39 GEP | 3% | 31% | 88% | 76% | RECIST | TTP 36 months | |
| Mean 25.5 GBq in 5 cycles, normal subjects; mean 17.8 GBq in risk patients (28) | 52 P | 8% | 21% | 81% | 88% | SWOG | PFS 20 months in reduced dosage, not reached in full dosage | |
| 32 GBq in 4 cycles (29) | 68 P | 0% | 60.3% | 85.3% | 67.6% | SWOG | PFS 34 months | |
| Median 25.7 vs. 18.4 GBq (normal vs. risk patients) (30) | 43 SI | 7% | 0% | 84% | 100% | SWOG | PFS 36 months | |
| 32 GBq in 4 cycles (31) | 61 SI | 0% | 13.1% | 91.8% | 75.4% | SWOG | PFS 33 months | |
| 27.8–29.6 GBq in 3–4 cycles vs. octreotide LAR 60 mg/month (32) | 201 SI | 19% (Lu) vs. 3% (LAR) CR + PR | 20% (Lu) vs. 58% (LAR) | 100% | RECIST | PFS not reached (Lu) vs. 8.4 months (LAR) | ||
PRRT, peptide receptor radionuclide therapy; GEP, gastroenteropancreatic; NET, neuroendocrine tumor; CR, complete response; PR, partial response; DCR, disease control rate; SI, small intestine; Lu, lutetium; LAR, long-acting release; PFS, progression-free survival; TTP, time to progression; NA, not assessed;